Universität zu Köln

2014

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M. and Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. Haematologica, 99. S. 249 - 251. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M. and Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. Haematologica, 99. S. 63 - 64. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M. and Sharman, J. P. (2014). EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 56 - 58. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A. and Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. Oncol. Res. Treat., 37. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262

Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H. and Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. Oncol. Res. Treat., 37. S. 52 - 54. BASEL: KARGER. ISSN 2296-5262

Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M. and Sharman, J. P. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 521 - 522. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Stilgenbauer, S., Hallek, M. J., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Coiffier, B., O'Brien, S. M., Tausch, E., Sharman, J. P., Ruppert, S., Schuster, A. and Kroenig, H. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262